Global Leading Market Research Publisher QYResearch announces the release of its latest report “Refractory Multiple Myeloma – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Refractory Multiple Myeloma market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hematologists and oncology providers managing multiple myeloma patients who have progressed through first- and second-line therapies, the core clinical challenge is overcoming dual resistance to immunomodulatory agents (lenalidomide, pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib, ixazomib). Patients with refractory multiple myeloma—defined as disease progression within 60 days of last treatment—have historically faced poor prognoses with median overall survival of 9-12 months and limited therapeutic options. However, the past five years have witnessed an unprecedented expansion in treatment modalities: next-generation immunomodulatory agents, novel proteasome inhibitors, anti-CD38 monoclonal antibodies (daratumumab, isatuximab), BCMA-targeted CAR-T therapies (idecabtagene vicleucel, ciltacabtagene autoleucel), bispecific T-cell engagers (teclistamab, elranatamab), and antibody-drug conjugates (belantamab mafodotin). This report delivers a data-driven analysis of market size, market share concentration across drug classes, and evolving treatment paradigms across hospitals and specialty oncology clinics.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5983921/refractory-multiple-myeloma
1. Market Size & Share Outlook: Biologics and Cell Therapies Reshape Late-Line Treatment
The global market for refractory multiple myeloma therapeutics is undergoing transformative growth, driven by the expanding addressable patient population, regulatory approvals of novel modalities, and increasing use of combination regimens in third-line and later settings. While specific 2025 and 2032 valuation figures were not provided in the source material, industry consensus and published market research indicate a compound annual growth rate (CAGR) in the high single digits to low double digits (estimated 8-12%) from 2025 through 2032, with CAR-T and bispecific antibody segments growing at 25-35% CAGR.
Recent market intelligence (Q1 2026): Preliminary supply-side data indicates that market share concentration among the top five pharmaceutical companies—Bristol Myers Squibb (CAR-T, immunomodulators), Janssen/Johnson & Johnson (anti-CD38, CAR-T, bispecifics), Pfizer (antibody-drug conjugate), GSK (anti-CD38, ADC), and Takeda (proteasome inhibitors)—remains significant at approximately 55-60% of the late-line segment. However, generic entry of lenalidomide (2026 in major markets) and pomalidomide (2027-2028) is reshaping early-line dynamics, with branded novel agents capturing increasing market share in refractory settings.
Global patient population context: Multiple myeloma is the second most common hematologic malignancy, with approximately 180,000 new cases diagnosed annually worldwide (GLOBOCAN 2025 estimates) and prevalence exceeding 500,000 patients. Approximately 20-25% of patients develop primary refractory disease (no response to first-line therapy), and an additional 30-40% become refractory to subsequent lines. The refractory multiple myeloma addressable patient population is estimated at 150,000-180,000 patients globally at any given time, growing at 3-5% annually as improved early-line therapies extend survival but increase cumulative exposure and resistance.
2. Therapeutic Deep Dive: Drug Class Evolution for Refractory Disease
Refractory multiple myeloma is defined as disease progression during or within 60 days of completing treatment with a given agent or regimen. Double-refractory (to immunomodulatory agents and proteasome inhibitors) and triple-refractory (to IMiDs, PIs, and anti-CD38) patient populations represent the highest unmet medical need.
Market segmentation by drug class:
- Proteasome Inhibitors (bortezomib – Takeda/Janssen; carfilzomib – Amgen/Onyx; ixazomib – Takeda) – Bortezomib remains widely used in first-line but has limited efficacy in bortezomib-refractory patients. Carfilzomib (second-generation, irreversible inhibitor) retains activity in some bortezomib-refractory patients, achieving 20-25% overall response rate (ORR) as monotherapy in heavily pretreated patients, increasing to 40-50% in combination with dexamethasone or IMiDs. Ixazomib (oral proteasome inhibitor) has modest single-agent activity in refractory settings (ORR 15-20%) but is used primarily in combination. Market share in refractory settings is declining from ~35% of third-line regimens in 2020 to ~25% in 2025, with further decline projected to 15-20% by 2030 as novel modalities expand.
- Immunomodulatory Agents (IMiDs) (lenalidomide – BMS; pomalidomide – BMS) – Lenalidomide-refractory disease (progression during or within 60 days of lenalidomide-based therapy) is increasingly common, affecting >50% of patients by third line. Pomalidomide retains activity in lenalidomide-refractory patients, with single-agent ORR 25-30% and 35-45% with dexamethasone. The pivotal phase 3 OPTIMISMM trial demonstrated pomalidomide, bortezomib, dexamethasone (PVd) achieved median progression-free survival (PFS) of 11.2 months vs. 7.1 months for Vd alone (HR 0.61) in lenalidomide-refractory patients. Market share of IMiDs in refractory settings remains stable at 30-35% of treatment regimens, primarily in combination with other agents.
- Anti-CD38 Monoclonal Antibodies (daratumumab – Janssen; isatuximab – Sanofi) – These agents have transformed refractory multiple myeloma treatment. Daratumumab as monotherapy (16 mg/kg weekly then every 2 weeks) achieves ORR 30-35% in patients refractory to IMiDs and PIs, with median PFS of 4-6 months. In combination with pomalidomide-dexamethasone (D-Pd), the APOLLO trial demonstrated ORR 69% vs. 46% (Pd alone), median PFS 12.4 vs. 6.9 months. Isatuximab combined with carfilzomib-dexamethasone (Isa-Kd) in IKEMA trial achieved median PFS 35.7 months vs. 19.2 months (Kd alone). Market share of anti-CD38 antibodies in refractory settings has grown from <5% in 2018 to approximately 35-40% of third-line regimens in 2025, projected to reach 45-50% by 2028.
- BCMA-Targeted CAR-T Therapies (idecabtagene vicleucel/ide-cel – BMS/bluebird bio; ciltacabtagene autoleucel/cilta-cel – Janssen/Legend) – These represent breakthrough options for triple-refractory (IMiD, PI, anti-CD38) patients. Pivotal phase 2 KarMMa trial (ide-cel) in 128 patients (median 6 prior lines, 84% triple-refractory) achieved ORR 73%, complete response (CR) 33%, median PFS 8.8 months. CARTITUDE-1 (cilta-cel, 97 patients, median 6 prior lines, 88% triple-refractory) achieved ORR 97%, CR 67%, median PFS not reached at 18 months. CAR-T therapies are currently limited by manufacturing lead time (3-5 weeks), cost (US$ 400,000-500,000 per infusion), and toxicity (cytokine release syndrome 80-95%, neurotoxicity 10-25%). Market share in refractory settings is approximately 10-15% of eligible patients (estimated 15,000-20,000 patients annually globally), projected to reach 25-30% by 2030 as manufacturing scales and earlier-line approvals expand.
- Bispecific T-Cell Engagers (BiTEs) (teclistamab – Janssen; elranatamab – Pfizer; talquetamab – Janssen) – Teclistamab (BCMA×CD3) received FDA approval 2022 for triple-refractory myeloma. Phase 1/2 MajesTEC-1 trial (165 patients, median 5 prior lines, 78% triple-refractory) achieved ORR 63%, CR 39%, median PFS 11.3 months. Elranatamab (MagnetisMM-3, 123 patients) achieved ORR 61%, CR 35%, median PFS not reached at 14-month follow-up. Advantages over CAR-T: off-the-shelf availability (no manufacturing delay), lower cost (estimated US$ 200,000-300,000 per initial course), more manageable toxicity (CRS 55-70%, mostly grade 1-2). Market share is rapidly expanding, estimated at 5-10% of refractory patients in 2025, projected to reach 20-25% by 2028.
- Antibody-Drug Conjugates (ADCs) (belantamab mafodotin – GSK) – BCMA-targeted ADC with monomethyl auristatin F (MMAF) payload. Phase 2 DREAMM-2 trial (196 patients, median 7 prior lines, triple-refractory) achieved ORR 31-34%, median PFS 2.6-2.9 months, but with significant ocular toxicity (keratopathy 70%, requiring dose delays). GSK withdrew US marketing authorization in 2022 but retains EU approval; ongoing trials evaluating alternative dosing schedules. Market share is limited (<5%) due to toxicity and availability of superior alternatives.
Industry insight (treatment setting segmentation): Refractory multiple myeloma care is increasingly segmented between hospital-based academic centers (where CAR-T administration requires specialized cellular therapy infrastructure, including apheresis, cryopreservation, lymphodepletion, and inpatient CRU monitoring) and specialty clinics/community oncology practices (where bispecific antibodies, anti-CD38 monoclonal antibodies, and combination IMiD/PI regimens are administered in outpatient settings). By 2028, we project CAR-T will remain concentrated in 150-200 academic centers globally, while bispecific antibodies will decentralize to 1,000+ community sites, fundamentally reshaping market share dynamics for pharmaceutical companies’ commercial infrastructure.
3. Market Drivers: Expanded Indications, Sequencing Strategies, and Globalization of Access
Three converging trends are accelerating adoption of novel therapies in refractory multiple myeloma:
First, earlier-line approvals for novel modalities. Daratumumab received approval for first-line transplant-eligible (2023) and transplant-ineligible (2024) patients, expanding the refractory pool for subsequent therapies. CAR-T therapies (ide-cel, cilta-cel) received FDA approval for fourth-line (2021) and are expected to receive third-line approval in 2026-2027 based on CARTITUDE-4 and KarMMa-3 trials showing superiority over standard regimens. Bispecific antibodies (teclistamab, elranatamab) are moving from fifth-line to fourth-line, with potential third-line approval by 2028. Each line advancement expands the addressable market share by 30-50%.
Second, optimized sequencing and combination strategies. The CASTOR trial demonstrated daratumumab + bortezomib-dexamethasone (DVd) superior to Vd alone in relapsed/refractory patients (median PFS 16.7 vs. 7.1 months). The POLLUX trial showed daratumumab + lenalidomide-dexamethasone (DRd) superiority over Rd (median PFS 44.5 vs. 17.5 months). These data established anti-CD38 combinations as standard of care in first relapse, indirectly defining the triple-refractory population (IMiD, PI, anti-CD38) as the target for CAR-T and BiTEs. Understanding optimal sequencing—anti-CD38 → BiTE → CAR-T versus BiTE → CAR-T versus CAR-T → BiTE—requires ongoing clinical investigation and will shape market share allocation among drug classes.
Third, global access expansion. China’s NMPA approved daratumumab (2019), isatuximab (2022), and teclistamab (2024) for refractory multiple myeloma, with ide-cel and cilta-cel approved 2023-2024. National Reimbursement Drug List (NRDL) inclusion for daratumumab (2021) and carfilzomib (2022) has expanded access to an estimated 50,000-70,000 Chinese patients annually. Similarly, Brazil’s ANS (Agência Nacional de Saúde Suplementar) mandated coverage for daratumumab (2023) and CAR-T (2024), opening Latin America’s largest market. These regulatory and reimbursement milestones are expanding the refractory multiple myeloma addressable market by an estimated 15-20% annually through 2028.
Typical user case (Q3 2025): A 62-year-old male with IgG kappa myeloma initially diagnosed 2018. Treatment history: VRD (bortezomib, lenalidomide, dexamethasone) first-line – progression at 18 months (lenalidomide-refractory); daratumumab, pomalidomide, dexamethasone (DPd) second-line – progression at 14 months (pomalidomide-refractory, daratumumab-refractory); now triple-refractory (lenalidomide, pomalidomide, daratumumab) with bortezomib-sensitive status unknown. At a US academic center, the patient received teclistamab (bispecific BCMA×CD3) as outpatient therapy: step-up dosing (0.06 mg/kg day 1, 0.3 mg/kg day 4, 1.5 mg/kg day 8) with dexamethasone premedication. Grade 1 CRS (fever, managed with tocilizumab) on day 9. By day 28 assessment: serum M-protein decreased from 3.2 g/dL to 0.4 g/dL (partial response, 87% reduction). Treatment continues with every 2-week maintenance dosing. Estimated cost: teclistamab US45,000initialcourse+US45,000initialcourse+US 18,000 per month maintenance vs. inpatient CAR-T at US$ 450,000 single infusion. The patient has returned to part-time work and maintains quality of life without hospitalization.
Policy and regulatory update (2025-2026): The European Medicines Agency (EMA) approved teclistamab for fourth-line refractory multiple myeloma (2022) and extended approval to third-line in October 2025 following positive CHMP opinion on confirmatory data. The US FDA granted regular approval to ciltacabtagene autoleucel (cilta-cel) in April 2025 for relapsed/refractory myeloma after 2 prior lines (previously fourth-line accelerated approval), significantly expanding eligible patient population. China’s NMPA included isatuximab in the 2025 NRDL, reducing patient out-of-pocket costs from US25,000percycletoapproximatelyUS25,000percycletoapproximatelyUS 2,000.
4. Competitive Landscape & Regional Market Share Dynamics
The Refractory Multiple Myeloma market is segmented as below:
Key players:
Bristol Myers Squibb (lenalidomide, pomalidomide, ide-cel CAR-T), Teva Pharmaceutical Industries Ltd. (generic bortezomib, cyclophosphamide), Pfizer Inc. (elranatamab bispecific, supportive care), Janssen Global Services, LLC (daratumumab, cilta-cel CAR-T, teclistamab bispecific, talquetamab bispecific), Gilead Sciences, Inc. (carfilzomib – through Kite/Amgen legacy), Fresenius Kabi (generic chemotherapies, supportive infusions), GSK plc. (belantamab mafodotin ADC), Novartis AG (generic IMiDs outside US, pipeline), Takeda Pharmaceutical Company Limited (bortezomib, ixazomib), Genentech, Inc. (Roche – pipeline bispecifics)
Segment by Drug Class:
- Proteasome Inhibitors (bortezomib generics, carfilzomib, ixazomib)
- Immunomodulatory Agents (lenalidomide generic entry 2026, pomalidomide)
- Anti-CD38 Monoclonal Antibodies (daratumumab, isatuximab)
- Others (CAR-T, bispecific antibodies, ADC, corticosteroids)
Segment by Treatment Setting:
- Hospital (academic medical centers, tertiary referral hospitals) – CAR-T administration, complex bispecific dose initiation
- Specialty Clinic (community oncology, private practice) – Anti-CD38 monoclonal antibodies, pomalidomide/dexamethasone, bispecific maintenance
- Others (ambulatory infusion centers)
Regional market share estimates 2025 (refractory segment therapeutics):
- North America: 45% (US 40%, Canada 5%) – Highest novel therapy adoption (CAR-T, bispecifics) and favorable reimbursement
- Europe: 28% (Germany 7%, UK 5%, France 5%, Italy 4%, others 7%) – Strong anti-CD38 adoption, CAR-T access concentrated
- Asia-Pacific: 18% (China 10%, Japan 5%, South Korea 2%, Australia 1%) – Fastest-growing, driven by NRDL inclusion and manufacturing scale-up
- Rest of World: 9% (Latin America, Middle East)
Exclusive insight (原创观察): A critical and underreported dynamic is the emergence of refractory multiple myeloma as a “chronic management” disease rather than a terminal condition. With median overall survival for triple-refractory patients improving from 9-12 months (2015) to 24-30 months (2025) due to novel therapies, treatment sequencing has become increasingly complex. Pharmaceutical companies are competing not only for initial market share in each line of therapy but for “share of patient journey”—capturing patients at first relapse (anti-CD38), second relapse (bispecific or second anti-CD38 combination), third relapse (CAR-T or alternative bispecific), and beyond. By 2028, we project that 40-50% of refractory multiple myeloma patients will receive three or more novel agent classes (anti-CD38, bispecific, CAR-T) over their treatment course, creating significant revenue durability but also challenging clinical decision-making for optimal sequencing.
5. Technical Hurdles and Future Research Directions
Despite remarkable progress, significant challenges remain:
- CAR-T manufacturing bottlenecks and vein-to-vein time: Current manufacturing capacity supports only 15-20% of eligible refractory multiple myeloma patients globally. Median vein-to-vein time (apheresis to infusion) is 4-6 weeks, with 10-15% of patients progressing or becoming too ill to receive therapy during this interval. Allogeneic (“off-the-shelf”) CAR-T, point-of-care manufacturing, and reduced manufacturing timelines (target 7-10 days) are active development priorities.
- Bispecific T-cell engager toxicity management: CRS occurs in 55-80% of patients receiving teclistamab/elranatamab, requiring hospitalization for step-up dosing in many centers. Late-onset neurotoxicity (ICANS, 5-15%) and prolonged cytopenias (neutropenia 40-50%, thrombocytopenia 30-40%) increase supportive care burden and cost. Developing predictive biomarkers for severe CRS remains an unmet need.
- Post-CAR-T relapse mechanisms: Approximately 40-50% of patients relapse within 12 months of CAR-T infusion. Mechanisms include antigen escape (BCMA-negative clones), CAR-T cell exhaustion, and host anti-CAR immunity. Second-line options post-CAR-T (alternative bispecifics, ADC, second CAR-T targeting different antigen like GPRC5D) are being studied but lack prospective trial data.
Future Market Research priorities should address:
- Dual-targeted CAR-T (BCMA/GPRC5D, BCMA/CD38) – Reducing antigen escape relapse; early-phase trials show promising activity
- Next-generation bispecifics with extended half-life – Reducing dosing frequency from weekly to monthly, improving patient convenience and reducing CRU burden
- Subcutaneous formulations of anti-CD38 antibodies – Daratumumab subcutaneous (co-formulated with hyaluronidase) reduces infusion time from 3-6 hours to 5 minutes, enabling community oncology administration and expanding market share
- Real-world evidence registries for sequencing decisions – Large-scale observational data comparing outcomes for anti-CD38 → BiTE → CAR-T vs. CAR-T → BiTE to inform clinical guidelines
- Combination biomarker strategies – Baseline tumor mutation burden, minimal residual disease (MRD) status, and cytokine profiles predicting response to each modality class
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
